Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Glioma × niraparib × Clear all

Phase

Status

Active not recruiting 2 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 8 Neoplasms 3 Endometrial Neoplasms 3 Breast Neoplasms 3 Pancreatic Neoplasms 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neutropenia 1 Neuroblastoma 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Glioma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Cystadenocarcinoma, Serous 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 19 Bevacizumab 10 Irinotecan 5 Radiotherapy 4 Topotecan 3 Magnetic Resonance Imaging 3 Carmustine 3 Carboplatin 3 Aminolevulinic Acid 3 ribociclib 2 poly ICLC 2 fluoromisonidazole 2 fluorodopa F 18 2 carmustine, poliferprosan 20 drug combination 2 cabozantinib 2 TIC10 compound 2 Surgical Procedures, Operative 2 Standard of Care 2 Re-Irradiation 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Panobinostat 2 O(6)-benzylguanine 2 Melphalan 2 Magnetic Resonance Spectroscopy 2 Lacosamide 2 Filgrastim 2 Dynamic Contrast Enhanced Magnetic Resonance Imaging 2 Doxorubicin 2 Congresses as Topic 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05297864 2025-05-23

OU-SCC-PI-4G

University of Oklahoma

Phase 2 Terminated

15 enrolled 13 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡